Cancer Diary: When a Vaccine Is NOT about Prevention

When most of us hear the word vaccine, we think of prevention.

A flu vaccine helps keep us from getting the flu. A shingles vaccine helps prevent shingles. Childhood vaccines protect us from diseases before they ever take hold.

So imagine my surprise when I learned about a new melanoma vaccine that is designed for people who have already had cancer.

That sounds backward at first.

But it represents one of the most intriguing developments in cancer treatment in recent years.

Recent clinical trial results from a personalized mRNA melanoma vaccine developed by Moderna and Merck showed a significant reduction in the risk of cancer recurrence when combined with the immunotherapy drug Keytruda. The vaccine is not intended for healthy people who want to avoid skin cancer someday. Rather, it is designed for patients who have already had melanoma removed and face the lingering question every cancer patient knows all too well:

Will it come back? [statnews.com], [time.com], [news.cance...archuk.org]

Teaching the Immune System What to Hunt

The idea behind the vaccine is surprisingly elegant.

Scientists analyze a patient's tumor and identify unique mutations that exist on those cancer cells. Using mRNA technology, they create a vaccine tailored specifically to that individual. The vaccine essentially trains the immune system to recognize those cancer "fingerprints" and attack any remaining cells carrying them. [statnews.com], [arstechnica.com]

In other words, the vaccine does not prevent cancer from appearing in the first place.

It helps the immune system find and destroy cancer cells that may still be hiding after treatment.

For many cancer survivors, that possibility is both fascinating and deeply encouraging.

A Different Way to Think About Vaccines

For decades, cancer treatment has relied on surgery, radiation, chemotherapy, and more recently immunotherapy.

Personalized cancer vaccines represent something different. They treat every patient's cancer as unique.

No two tumors are exactly alike. The vaccine is built specifically for the mutations found in one person's cancer. What is manufactured for one patient would not necessarily work for another. [news.cance...archuk.org], [arstechnica.com]

That level of personalization would have sounded like science fiction not very long ago.

Today it is being tested in large clinical trials.

A Realistic Note

As exciting as these findings are, it is important to keep expectations grounded.

The vaccine is currently being studied for melanoma, one of the most serious forms of skin cancer. The strongest evidence so far comes from patients whose tumors were surgically removed and who were considered at high risk for recurrence. It is not yet a routine treatment for all skin cancers, and researchers are still learning how broadly this approach can be applied to other types of cancer. [time.com], [news.cance...archuk.org]

Science advances one step at a time.

Still, this is one of those steps worth noticing.

Why This Matters

Every cancer survivor understands that treatment does not always end when the surgery ends.

Even after the scans are clear, many people live with uncertainty. Follow-up appointments, blood tests, and imaging studies become milestones marking the passage of time.

The promise of a personalized cancer vaccine is not simply that it fights cancer.

The promise is that it may help keep cancer from returning.

That is a different goal from traditional vaccines, but for those living in the shadow of recurrence, it may be every bit as important.

Perhaps the most remarkable thing about this breakthrough is not the technology itself.

It is the reminder that medicine continues to move forward, finding new ways to enlist the body's own defenses in the fight against disease.

For cancer patients, survivors, and families, that is news worth celebrating.

For Further Reading

• TIME: "A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42%"
  https://time.com/article/2026/10/22/moderna-merck-immunotherapy-lowers-melanoma-recurrence/

• Cancer Research UK: "Personalised cancer vaccine cuts risk of melanoma returning"
  https://news.cancerresearchuk.org/2026/10/23/esmo-2026-updates/

Author's Note: This post discusses melanoma, the most serious form of skin cancer. The vaccine described here is a therapeutic cancer vaccine designed for people who have already had melanoma and undergone treatment. It is not a preventive vaccine for the general public.

image and some content/research AI-generated

For other Cancer Diary posts, click HERE.

Blog editor's note: As a memorial to Carl, and simply because it is truly needed, MSI Press is now hosting a web page, Carl's Cancer Compendium, as a one-stop starting point for all things cancer, to make it easier for those with cancer to find answers to questions that can otherwise take hours to track down on the Internet and/or from professionals. The CCC is expanded and updated weekly. As part of this effort, each week, on Monday, this blog will carry an informative, cancer-related story -- and be open to guest posts: Cancer Diary. 

MSI Press, a veteran-owned publishing house based in California, United States

best known for turning new writers into award-winning authors,
has gained mass recognition for releasing highly acclaimed books of varying genres
that are distributed internationally. Check us out on Wikitia.

To purchase copies of any MSI Press book at 25% discount,

use code FF25 at MSI Press webstore;

for free shipping, use code ship4free.

(Codes cannot be used together; they are meant to provide a choice of discount.)

Want to read an MSI Press book and not have to pay for it?

(1) Ask your local library to purchase and shelve it.
(2) Ask us for a review copy; we love to have our books reviewed.

VISIT OUR WEBSITE TO LEARN MORE ABOUT ALL OUR AUTHORS AND TITLES.

Sign up for the MSI Press LLC monthly newsletter: get inside information before others see it and access to additional book content

(recent releases, sales/discounts, awards, reviews, Amazon top 100 list, links to precerpts/excerpts, author advice, and more)

Check out recent issues.

 

 

Follow MSI Press on Twitter, Face Book, Pinterest, and Bluesky. 

 

 

MSI Press welcomes submissions that reflect legacy and lived experience. Learn more about our publishing process on our website. We help writers become award-winning published authors, one writer at a time. We are a family, not a factory. Check our listing in Writer's Market, the most trusted guide to publishing.

Turned away by other publishers because you are a first-time author and/or do not have a strong platform yet? If you have a strong manuscript, San Juan Books, our hybrid publishing division, may be able to help. Ask us. Check out more information at www.msipress.com.

 

Planning on self-publishing and don't know where to start? Our author au pair services will mentor you through the process. See what we can do for your at www.msipress.com.

Interested in receiving a free copy of this or any MSI Press LLC book in exchange for reviewing a current or forthcoming MSI Press LLC book? Contact editor@msipress.com.

Want an author-signed copy of this book? Purchase the book at 25% discount (use coupon code FF25) and concurrently send a written request to orders@msipress.com.

Julia Aziz, signing her book, Lessons of Labor, at an event at Book People in Austin, Texas.

Want to communicate with one of our authors? You can! Find their contact information on our Authors' Pages.

Steven Greenebaum, author of award-winning books, An Afternoon's Discussion and One Family: Indivisible, talking to a reader at Barnes & Noble in Gilroy, California.

   

MSI Press is ranked among the top publishers in California.
Check out our rankings -- and more -- HERE.